Intervention Review

You have free access to this content

Mycobacterium vaccae immunotherapy for treating tuberculosis

  1. Guy de Bruyn1,*,
  2. Paul Garner2

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 20 JAN 2010

Assessed as up-to-date: 4 OCT 2002

DOI: 10.1002/14651858.CD001166

Database Title

Additional Information

How to Cite

de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD001166. DOI: 10.1002/14651858.CD001166.

Author Information

  1. 1

    Wits Health Consortium, Perinatal HIV Research Unit, Johannesburg, Guateng, South Africa

  2. 2

    Liverpool School of Tropical Medicine, International Health Group, Liverpool, Merseyside, UK

*Guy de Bruyn, Perinatal HIV Research Unit, Wits Health Consortium, PO Box 114, Diepkloof, Johannesburg, Guateng, 1864, South Africa. debruyng@phru.co.za.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 20 JAN 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (59K)Standard (232K)Full (316K)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Corlan 1997a {published data only}
  • Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease. Respiratory Medicine 1997;91(1):13-9.
Corlan 1997b {published data only}
  • Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respiratory Medicine 1997;91(1):21-9.
DITG 1999 {published data only}
  • Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999;354(9173):116-9.
Johnson 2000 {published data only}
  • Johnson JL, Kamya RM, Okwera A, Loughlin AM, Nyole S, Hom SL, et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. Journal of Infectious Diseases 2000;181(4):1304-12.
Kon 1998 {published data only}
Mwinga 2002 {published data only}
  • Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002;360(9339):1050-5.
Stanford 1990 {published data only}
  • Bahr GM, Stanford JL, Chugh TD, Shaaban MA, Gabriel M, Al-Shimali B, et al. An investigation of patients with pulmonary tuberculosis in Kuwait in preparation for studies of immunotherapy with Mycobacterium vaccae. Tubercle 1990;71(2):77-86.
  • Stanford JL, Bahr GM, Rook GA, Shaaban MA, Chugh TD, Gabriel M, et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 1990;71(2):87-93.
Wang 1999 {published data only}
  • Wang W, Jin G, Ye Y, Xia X, Wang A, Zhang Y, et al. A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 1999;22(2):108-10.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Bahr 1990 {published data only}
Bottasso 1995 {published data only}
  • Bottasso OA, Vacirca A, Dominino J, Valentini E, Hartopp R. Immunotherapy applied [a pilot study of immunotherapy with M.vaccae against tuberculosis]. Tubercle and Lung Disease 1995;76 Suppl 2:9.
Corrah unpublished {unpublished data only}
  • Corrah T. Trial of M. vaccae from the Medical Research Council Unit in The Gambia. Unpublished.
Dlugovitzky 1999 {published data only}
  • Dlugovitzky D, Bottasso O, Dominino JC, Valentini E, Hartopp R, Singh M, et al. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respiratory Medicine 1999;93(8):557-62.
Huong unpublished {unpublished data only}
  • Professors Huong, Linh. Trial of M. vaccae. Unpublished.
Luo 2000 {published data only}
  • Luo Y, Lu S, Guo S. Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2000;23(2):85-8.
Luo 2001 {published data only}
  • Luo Y, National Cooperation Group on Clinical Study of Mycobacterium Vaccae Vaccine. The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2001;24(1):43-7.
Mayo 2000a {published data only}
  • Mayo RE, Stanford JL. Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000;94(5):563-8.
Onyebujoh 1995 {published data only}
  • Onyebujoh PC, Abdulmumini T, Robinson S, Rook GA, Stanford JL. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respiratory Medicine 1995;89(3):199-207.
Vacirca 1994 {published data only}
  • Vacirca A, Dominino J, Valentini E, Hartopp R, Bottasso OA. A pilot study of immunotherapy with M. vaccae against tuberculosis. Tubercle and Lung Disease 1994;75 Suppl 1:47-8.
Waddell 2000b {published data only}
  • Waddell RD, Chintu C, Lein AD, Zumla A, Karagas MR, Baboo KS, et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clinical Infectious Diseases 2000;30 Suppl 3:309-15.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Abramson 2000
  • Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: ]
Barnes 2000
  • Barnes PF, Wizel B. Type 1 cytokines and the pathogenesis of tuberculosis. American Journal of Respiratory and Critical Care Medicine 2000; Vol. 161, issue 6:1773-4.
Bousquet 1998
Convit 1989
  • Convit J, Castellanos PL, Ulrich M, Castes M, Rondon A, Pinardi ME, et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. Journal of Infectious Diseases 1989;160(1):104-15.
Ewan 1998
Grange 1998
  • Grange JM. Pathogenesis of mycobacterial disease. In: Gangadharam PRJ, Jenkins PA editor(s). Mycobacteria. Vol. 1: Basic Aspects, New York: Chapman-Hall, 1998:145-77.
Jüni 2001
Kahn 2000
  • Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA 2000;284(17):2193-202.
Review Manager 5
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Rook 1994
  • Rook GA, Onyebujoh P, Wilkins E, Ly HM, al Attiyah R, Bahr G, et al. A longitudinal study of per cent agalotosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy. Immunology 1994;81(1):149-54.
Rook 1996
  • Rook GA, Stanford JL. The Koch phenomenon and the immunopathology of tuberculosis. In: Shinnick TM editor(s). Current Topics in Microbiology and Immunology. Vol. 215, Berlin: Springer-Verlag, 1996:239-62.
Stanford 1990a
Stanford 1994
Straus 1997
  • Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman P, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. Journal of Infectious Diseases 1997;176(5):1129-34.
Weber 1997
Zuany-Amorim 2002
  • Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, Kemeny DM, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nature Medicine 2002;8(6):625-9.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
de Bruyn 1998
  • de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for TB. Cochrane Database of Systematic Reviews 1998, Issue 3.
de Bruyn 1999
  • de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database of Systematic Reviews 1999, Issue 4. [Art. No.: CD001166. DOI: ]
de Bruyn 2000
  • de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database of Systematic Reviews 2000, Issue 2. [Art. No.: CD001166. DOI: ]
de Bruyn 2003
  • de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: ]
View Full Article (HTML) Summary (59K)Standard (232K)Full (316K)